Suven Life Sciences (Suven) has announced that its clinical candidate SUVN-502 for Alzheimer’s disease secured several product patents granted at all the key market countries such as India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe. The product patents for SUVN-502 in all the countries are valid until June 2023. SUVN-502 is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts. The granted patent has been validated in all the nine member countries of Eurasia (including Russia) and 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.
SUVN-502 completed the Phase-I single ascending and multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested with excellent bioavailability and half life for potential once in a day treatment. Suven is planning to initiate the clinical phase-II proof-of-concept (POC) studies during 2010. The company targets launching of SUVN-502 in later part of 2013 or early part of 2014.
SUVN-502 completed the Phase-I single ascending and multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested with excellent bioavailability and half life for potential once in a day treatment. Suven is planning to initiate the clinical phase-II proof-of-concept (POC) studies during 2010. The company targets launching of SUVN-502 in later part of 2013 or early part of 2014.
No comments:
Post a Comment